Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9)

Comparison of Patients Hospitalized With Influenza A Subtypes H7N9, H5N1, and 2009 Pandemic H1N1

(2014) Chen Wang et al.   CLINICAL INFECTIOUS DISEASES

Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 Adjuvant

(2014) Mark J. Mulligan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity in Intravenous Immunoglobulin as a Potential Therapeutic Against Emerging Influenza Viruses

(2014) S. Jegaskanda et al.   JOURNAL OF INFECTIOUS DISEASES

A Live Attenuated Influenza A(H5N1) Vaccine Induces Long-Term Immunity in the Absence of a Primary Antibody Response

(2014) Kawsar R. Talaat et al.   JOURNAL OF INFECTIOUS DISEASES

Development of a High-Yield Live Attenuated H7N9 Influenza Virus Vaccine That Provides Protection against Homologous and Heterologous H7 Wild-Type Viruses in Ferrets

(2014) Z. Chen et al.   JOURNAL OF VIROLOGY

Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo

(2014) David J DiLillo et al.   NATURE MEDICINE

A Cell Culture-Derived MF59-Adjuvanted Pandemic A/H7N9 Vaccine Is Immunogenic in Adults

(2014) S. A. Bart et al.   Science Translational Medicine

Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine

(2014) Tara M. Babu et al.   VACCINE

Case-control study of risk factors for human infection with influenza A(H7N9) virus in Jiangsu Province, China, 2013

(2013) J Ai et al.   Eurosurveillance

Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity Antibodies in the Absence of Neutralizing Antibodies

(2013) S. Jegaskanda et al.   JOURNAL OF IMMUNOLOGY

Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect

(2013) Julie E. Ledgerwood, Kathryn Zephir, Zonghui Hu, Chih-Jen Wei, LeeJah Chang, Mary E. Enama, Cynthia S. Hendel, Sandra Sitar, Robert T. Bailer, Richard A. Koup, John R. Mascola, Gary J. Nabel, Barney S. Graham et al.   JOURNAL OF INFECTIOUS DISEASES

Clinical Findings in 111 Cases of Influenza A (H7N9) Virus Infection

(2013) Hai-Nv Gao et al.   NEW ENGLAND JOURNAL OF MEDICINE

An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults

(2012) Kawsar R. Talaat et al.   Influenza and Other Respiratory Viruses

Design and Performance of the CDC Real-Time Reverse Transcriptase PCR Swine Flu Panel for Detection of 2009 A (H1N1) Pandemic Influenza Virus

(2011) Bo Shu et al.   JOURNAL OF CLINICAL MICROBIOLOGY

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

(2011) Julie E Ledgerwood et al.   LANCET INFECTIOUS DISEASES

A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins

(2011) D. Corti et al.   SCIENCE

Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays

(2011) Barry Lorbetskie et al.   VACCINE

An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults

(2011) Kawsar R. Talaat et al.   VACCINE

A Live Attenuated H9N2 Influenza Vaccine Is Well Tolerated and Immunogenic in Healthy Adults

(2009) Ruth A. Karron et al.   JOURNAL OF INFECTIOUS DISEASES

A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults

(2009) Kawsar R. Talaat et al.   VACCINE

Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults

(2009) Ruth A. Karron et al.   VACCINE